{{Rsnum
|rsid=1401417
|Gene=CRY2
|Chromosome=11
|position=45858559
|Orientation=minus
|GMAF=0.1538
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=CRY2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 6.2 | 35.4 | 58.5
| HCB | 2.2 | 22.2 | 75.6
| JPT | 0.0 | 31.8 | 68.2
| YRI | 0.0 | 20.6 | 79.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.2 | 22.2 | 75.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19318546
|Title=Clock-Cancer Connection in Non-Hodgkin's Lymphoma: A Genetic Association Study and Pathway Analysis of the Circadian Gene Cryptochrome 2.
|OA=1
}}
{{PMID Auto
|PMID=20233903
|Title=The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling
|OA=1
}}

{{PMID|17984998}} Variants in circadian genes and prostate cancer risk: a population-based study in China.

{{PMID|18990770}} Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I.

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}